On October 7, 2011, the FDA approved an oral combination of sitagliptin/simvastatin marketed in the US as Juvisync.
On October 7, 2011, the FDA gave approval for an oral drug that included both sitagliptin and simvastatin, with the product known as Juvisync being sold in the United States.